Akeso says Phase 3 HARMONi-GI1 trial of ivonescimab met overall survival endpoint in biliary tract cancer

Summit Therapeutics partner Akeso announced Sunday that the Phase 3 HARMONi-GI1 trial met its overall survival superiority endpoint for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer.

Detected & updated continuously · Source: Nebula